甘李藥業(603087.SH):賴脯胰島素注射液獲黎巴嫩註冊批件
格隆匯8月24日丨甘李藥業(603087.SH)公佈,近日,公司收到黎巴嫩藥監局(MoPH)核准簽發的賴脯胰島素注射液的註冊批件(批件號:87614/1)。
賴脯胰島素注射液屬於速效胰島素類似物產品,又稱第三代餐時胰島素,進餐時立即注射15min起效,30~60min達到峯值,作用持續4~5h。由於賴脯胰島素經皮下注射吸收較快,與人胰島素相比,其降血糖作用起效更快,作用峯值更高,維持作用時間較短,可更好地控制餐後高血糖而較少引起低血糖,患者依從性更佳。
截至 2021年3月31日,公司在賴脯胰島素研發項目上已累計投入約2.75億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.